Iovance Biotherapeutics developed Amtagvi, an innovative medicine approved for advanced melanoma. Despite stock decline, Wall Street has faith in the company with a potential upside of 261%. Amtagvi requires complex manufacturing and has high expenses, but generated $60 million in revenue in the second quarter.

Potential expansions in Canada and Europe could boost market, targeting more melanoma patients in the U.S. Amtagvi might see label expansions for other cancers, increasing market potential. However, the biotech remains risky due to high costs and cash constraints. Investors cautious about clinical and regulatory hurdles with Amtagvi.

While risky, investors might consider a small position due to innovative potential. The Motley Fool’s top 10 stocks did not include Iovance Biotherapeutics. Stock Advisor has a total average return of 1,057%, outperforming the S&P 500. Consider joining for the latest top stock picks and potential returns.

Read more at Yahoo Finance: 1 Beaten-Down Stock That Could Soar By 261%, According to Wall Street